小细胞肺癌的管理 - Suppr

Suppr

超能文献

Management of small-cell cancer of the lung.

作者信息

Hansen H H

机构信息

Department of Oncology, Finsen Institute/Rigshospitalet, Copenhagen, Denmark.

出版信息

Lancet. 1992 Apr 4;339(8797):846-9. doi: 10.1016/0140-6736(92)90287-d.

DOI:10.1016/0140-6736(92)90287-d

PMID:1347865

Abstract

摘要

相似文献

Management of small-cell cancer of the lung.小细胞肺癌的管理

Lancet. 1992 Apr 4;339(8797):846-9. doi: 10.1016/0140-6736(92)90287-d.

Small cell lung cancer.小细胞肺癌

Acta Oncol. 1989;28(5):729-41. doi: 10.3109/02841868909092304.

Practice guidelines for small cell lung cancer.

Cancer J Sci Am. 1996 May-Jun;2(3A Suppl):S69-75.

The management of small cell lung cancer.小细胞肺癌的管理

N Z Med J. 1986 Feb 26;99(796):104-6.

Small-cell lung cancer: a curable disease?小细胞肺癌：一种可治愈的疾病？

Br J Dis Chest. 1979 Oct;73(4):327-48.

NCCN: Small cell lung cancer.美国国立综合癌症网络（NCCN）：小细胞肺癌。

Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):32-43.

Current perspectives in small cell lung cancer.小细胞肺癌的当前观点

Chest. 1984 May;85(5):669-77. doi: 10.1378/chest.85.5.669.

Management of small-cell lung cancer: time to move forward.小细胞肺癌的管理：是时候向前迈进了。

Oncology (Williston Park). 2010 Oct;24(11):1043, 1046-7.

Small cell cancer of the lung.肺小细胞癌

Clin Chest Med. 1982 May;3(2):389-98.

Treatment of small cell lung cancer - 1981.小细胞肺癌的治疗——1981年。

Arch Intern Med. 1981 Oct;141(11):1499-501.

引用本文的文献

Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer.每两周一次的伊立替康是治疗复发或难治性小细胞肺癌的一种有效且便捷的治疗方案。

BMC Cancer. 2024 Oct 1;24(1):1218. doi: 10.1186/s12885-024-12935-x.

Treatment Sequencing Strategies in Lung Cancer.肺癌的治疗序贯策略。

Zhongguo Fei Ai Za Zhi. 2022 May 20;25(5):323-336. doi: 10.3779/j.issn.1009-3419.2022.104.01.

Evaluation of topotecan monotherapy for relapsed small-cell lung cancer after amrubicin monotherapy failure.拓扑替康单药治疗阿柔比星单药治疗失败后的复发性小细胞肺癌的疗效评估。

J Rural Med. 2021 Oct;16(4):250-255. doi: 10.2185/jrm.2021-014. Epub 2021 Oct 1.

Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.伊立替康、拓扑替康、紫杉醇或多西他赛用于小细胞肺癌二线治疗：一项单中心疗效比较及预后分析的回顾性研究

Transl Lung Cancer Res. 2019 Dec;8(6):829-837. doi: 10.21037/tlcr.2019.10.21.

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer.对敏感复发小细胞肺癌进行一线铂类化疗再挑战。

Case Rep Oncol. 2018 Sep 7;11(3):622-632. doi: 10.1159/000492780. eCollection 2018 Sep-Dec.

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.伊立替康、顺铂和依托泊苷用于敏感复发性小细胞肺癌的多机构II期试验。

Br J Cancer. 2004 Aug 16;91(4):659-65. doi: 10.1038/sj.bjc.6602056.

Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.免疫组织化学法检测小细胞肺癌和非小细胞肺癌中的DNA拓扑异构酶IIα、P-糖蛋白及多药耐药蛋白（MRP）

Br J Cancer. 1998 May;77(9):1469-73. doi: 10.1038/bjc.1998.241.

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.表柔比星与口服依托泊苷门诊治疗小细胞肺癌患者

Br J Cancer. 1997;76(5):639-42. doi: 10.1038/bjc.1997.438.

Efficacy and safety of prophylactic cranial irradiation in patients with small cell lung cancer.预防性颅脑照射在小细胞肺癌患者中的疗效与安全性

J Neurooncol. 1997 Nov;35(2):153-60. doi: 10.1023/a:1005761825766.

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.七种耐药小细胞肺癌细胞系的体外交叉耐药性和协同敏感性：多西他赛、紫杉醇、拓扑替康和吉西他滨合适联合用药伙伴的临床前鉴定

Br J Cancer. 1997;75(6):869-77. doi: 10.1038/bjc.1997.154.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验